Virally encoded single-chain antibody fragments targeting alpha-synuclein protect against motor impairments and neuropathology in a mouse model of synucleinopathy

Abstract

Parkinsons disease (PD) is a neurodegenerative disorder mainly characterized by the loss of dopaminergic neurons from the substantia nigra. Affected neurons exhibit intracellular aggregates primarily composed of misfolded and phosphorylated alpha-synuclein (aSyn). In pathological conditions, this presynaptic protein has been shown to be transmitted from cell to cell in a prion-like manner, which contributes to the progression of the disease. Single-chain variable fragments (scFvs) are small polypeptides derived from the binding domains of antibodies that are less immunogenic and have better tissue penetration compared to full antibodies. In this work, we aimed to demonstrate the potential of extracellular scFvs to slow down the propagation of pathological aSyn in an in vivo model of synucleinopathy. We generated scFvs that target aSyn, and tested two of them in a PD mouse model consisting of transgenic M83 mice injected with human aSyn pre-formed fibrils (PFFs). The sequence encoding each anti-aSyn scFv was cloned in a self-complementary AAV2 viral vector, and purified particles were administered intravenously. CNS expression of either scFv protected against the development of paralysis and limb weakness, in addition to significantly reducing pathologic aggregates of phosphorylated aSyn in the brain. Moreover, in vitro results in human iPSCs-derived dopaminergic neurons suggest that the scFvs can mitigate aSyn spreading by preventing its internalization. Overall, our findings demonstrate that single-chain antibody fragments exhibit strong therapeutic potential in a preclinical mouse model. Thus, our minimally invasive, gene-mediated immunotherapy approach has the potential to serve as an effective treatment for halting the progression of Lewy body diseases.